Alpha Tau Medical Ltd.
NASDAQ:DRTSBiotechnology
Healthcare
$12.01 +0.42%
+$0.04 today
- Market cap
- $1.11B
- Beta
- 1.20
- P/E (TTM)
- -15.2
- EPS (TTM)
- -$0.63
52W Low $2.85High $11.62
Volume 0.64M
Average 0.69M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$26.68M
FY 2025 · Annual
Investing Cash Flow
-$20.59M
FY 2025 · Annual
Financing Cash Flow
$45.77M
FY 2025 · Annual
+182972.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.27M) | (33.76M) | (29.16M) | (31.75M) | (42.63M) |
| Depreciation & Amortization | 776K | 979K | 1.07M | 1.1M | 1.23M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 812K | 6.75M | 7.93M | 9.92M | 0 |
| Change in Working Capital | 585K | (307K) | 2.49M | 1.17M | 2.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 239K | 220K | 1.14M | 965K | 337K |
| Other Working Capital | 346K | (527K) | 1.35M | 203K | 1.95M |
| Other Non-Cash Items | 13.29M | 2.46M | (293K) | (219K) | 12.42M |
| Operating Cash Flow | (11.81M) | (23.88M) | (17.96M) | (19.78M) | (26.68M) |
| Capital Expenditures | (2.93M) | (904K) | (6.4M) | (2.24M) | (6.08M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (125.08M) | (70.49M) |
| Sales of Investments | 0 | 0 | 0 | 148.19M | 55.98M |
| Other Investing Activities | 22.2M | (89.03M) | 25.08M | (103K) | 0 |
| Investing Cash Flow | 19.27M | (89.94M) | 18.68M | 20.77M | (20.59M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 111K | 3.36M | 49K | 25K | 45.77M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 93.54M | 5.25M | 0 | 0 |
| Financing Cash Flow | 111K | 96.91M | 5.3M | 25K | 45.77M |
| Effect of Forex Changes | 108K | (258K) | 3.1M | 160K | 501K |
| Net Change in Cash | 7.68M | (17.17M) | 9.12M | 1.17M | (1M) |
| Free Cash Flow | (14.74M) | (24.78M) | (24.36M) | (22.02M) | (32.76M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$42.6M
+ D&A$1.2M
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$2.3M
+ Other Non-Cash$12.4M
= Operating Cash Flow-$26.7M
- Capex-$6.1M
= Free Cash Flow-$32.8M
Analysis
FY2025 free cash flow is -$32.8M. FCF conversion is 76.8% of net income. Operating cash flow was -$26.7M, with capex of -$6.1M. The largest bridge item is Other Non-Cash at $12.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 12, 2026 | |
| 6-K | 6-K filing | Oct 29, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| 6-K | 6-K filing | Oct 19, 2026 | |
| 6-K | 6-K filing | Aug 31, 2026 |
Does DRTS generate free cash flow?
Alpha Tau Medical Ltd. (DRTS) generated -$32.76M of free cash flow in fiscal 2025.
How much operating cash flow does DRTS produce?
Operating cash flow was -$26.68M, before capital expenditures of $6.08M.
Continue the stock analysis
Jump to another research area for this company.